Interferon beta-1a

Avonex(interferon beta-1a)

Avonex, Rebif (interferon beta-1a) is a protein pharmaceutical. Interferon beta-1a was first approved as Avonex on 1996-05-17. It is used to treat multiple sclerosis in the USA. It has been approved in Europe to treat multiple sclerosis.

Download report

Favorite

Top 200 Pharmaceuticals by Retail Sales

Events Timeline

Commercial

Clinical

Drug

Target

Variants

Financial

Trends

Safety

Events Timeline

YTD

Max

Events

FDA approval date

EMA approval date

Patent expiration date

Study first post date

Last update post date

Start date

Primary completion date

Completion date

Results first post date

Mock data
Subscribe for the real data

Commercial

Therapeutic Areas

Therapeutic Area	MeSH
nervous system diseases	D009422
immune system diseases	D007154

Trade Name

FDA

EMA

Avonex, Rebif (discontinued: Avonex)

Drug Products

FDA

EMA

Reference product - 351(a)

Interchangeable product - 351(k)

Biosimilar product - 351(k)

Interferon beta-1a

Tradename	Proper name	Company	Number	Date	Products
Avonex	interferon beta-1a	Biogen	N-103628 RX	2003-05-28	2 products
Rebif	interferon beta-1a	EMD Serono	N-103780 RX	2002-03-07	6 products

Show 1 discontinued

Labels

FDA

EMA

Brand Name	Status	Last Update
avonex	Biologic Licensing Application	2016-03-31
avonex avonex avonex pen	Biologic Licensing Application	2020-12-16
avonex avonex pen	Biologic Licensing Application	2024-11-13
rebif	Biologic Licensing Application	2010-01-14
rebif rebif rebidose	Biologic Licensing Application	2025-09-22

Indications

FDA

EMA

Indication	Ontology	MeSH	ICD-10
multiple sclerosis	EFO_0003885	D009103	G35

Agency Specific

FDA

EMA

Expiration	Code
interferon beta-1a, Avonex, Biogen Inc.
2103-05-17	Orphan excl.

Patent Expiration

No data

ATC Codes

L: Antineoplastic and immunomodulating agents

— L03: Immunostimulants

— L03A: Immunostimulants

— L03AB: Interferons

— L03AB07: Interferon beta-1a

HCPCS

Code	Description
J1826	Injection, interferon beta-1a, 30 mcg
Q3027	Injection, interferon beta-1a, 1 mcg for intramuscular use
Q3028	Injection, interferon beta-1a, 1 mcg for subcutaneous use

Clinical

Clinical Trials

247 clinical trials

View more details

Mock data
Subscribe for the real data

Indications Phases 4

Indication	MeSH	Ontology	ICD-10	Ph 1	Ph 2	Ph 3	Ph 4	Other	Total
Multiple sclerosis	D009103	EFO_0003885	G35	8	23	31	28	63	151
Relapsing-remitting multiple sclerosis	D020529	EFO_0003929	—	4	15	31	29	29	107
Sclerosis	D012598	—	—	1	8	6	15	18	47
Covid-19	D000086382	—	U07.1	—	4	7	2	3	15
Injection site reaction	D000075662	—	—	—	—	—	1	1	2
Optic neuritis	D009902	EFO_0007405	H46	—	—	—	2	—	2
Erythema	D004890	—	L53.9	—	—	—	1	—	1
Transverse myelitis	D009188	—	G37.3	—	—	—	1	—	1
Cerebellar diseases	D002526	—	—	—	—	—	1	—	1
Neuritis	D009443	—	—	—	—	—	1	—	1

Show 2 more

Indications Phases 3

Indication	MeSH	Ontology	ICD-10	Ph 1	Ph 2	Ph 3	Ph 4	Other	Total
Recurrence	D012008	—	—	—	2	3	—	2	7
Coronavirus infections	D018352	EFO_0007224	B34.2	—	2	3	—	1	5
Respiratory distress syndrome	D012128	EFO_1000637	J80	—	—	1	—	1	2
Coronavirus	D017934	—	—	—	1	1	—	1	2
Autoimmune diseases	D001327	EFO_0000540	M30-M36	—	1	1	—	—	2
Sars-cov-2	D000086402	—	—	—	1	1	—	—	2
Severe acute respiratory syndrome	D045169	EFO_0000694	J12.81	—	—	2	—	—	2
Pneumonia	D011014	EFO_0003106	J18	—	—	1	—	—	1
Thinness	D013851	—	R63.6	—	—	1	—	—	1
Respiratory insufficiency	D012131	—	J96.9	—	—	1	—	—	1

Show 1 more

Indications Phases 2

Indication	MeSH	Ontology	ICD-10	Ph 1	Ph 2	Ph 3	Ph 4	Other	Total
Ulcerative colitis	D003093	EFO_0000729	K51	—	3	—	—	—	3
Asthma	D001249	EFO_0000270	J45	—	2	—	—	—	2
Infections	D007239	EFO_0000544	—	—	1	—	—	—	1
Chronic obstructive pulmonary disease	D029424	EFO_0000341	J44.9	—	1	—	—	—	1
Multiple organ failure	D009102	EFO_1001373	—	—	1	—	—	—	1
Respiratory tract infections	D012141	—	J06.9	—	1	—	—	—	1
Alzheimer disease	D000544	EFO_0000249	F03	—	1	—	—	—	1
Dementia	D003704	EFO_0003862	F03	—	1	—	—	—	1
Crohn disease	D003424	EFO_0000384	K50	—	1	—	—	—	1
Disease progression	D018450	—	—	—	1	—	—	—	1

Show 22 more

Indications Phases 1

Indication	MeSH	Ontology	ICD-10	Ph 1	Ph 2	Ph 3	Ph 4	Other	Total
Healthy volunteers/patients	—	—	—	10	—	—	—	—	10
Pharmacokinetics	D010599	—	—	1	—	—	—	—	1
Pharmacological phenomena	D000069437	—	—	1	—	—	—	—	1
Therapeutic equivalency	D013810	—	—	1	—	—	—	—	1
Respiratory aspiration	D053120	EFO_1001839	—	1	—	—	—	—	1
Renal insufficiency	D051437	—	N19	1	—	—	—	—	1
Stroke	D020521	EFO_0000712	I63.9	1	—	—	—	—	1
Ischemia	D007511	EFO_0000556	—	1	—	—	—	—	1
Inflammation	D007249	MP_0001845	—	1	—	—	—	—	1

Indications Without Phase

Indication	MeSH	Ontology	ICD-10	Ph 1	Ph 2	Ph 3	Ph 4	Other	Total
Acute kidney injury	D058186	—	N17	—	—	—	—	1	1
Iatrogenic disease	D007049	—	—	—	—	—	—	1	1
Chronic progressive multiple sclerosis	D020528	EFO_0003840	—	—	—	—	—	1	1
Atrophy	D001284	—	—	—	—	—	—	1	1
Patient satisfaction	D017060	—	—	—	—	—	—	1	1
Motor activity	D009043	EFO_0003940	—	—	—	—	—	1	1
Exercise	D015444	EFO_0000483	—	—	—	—	—	1	1
Medication adherence	D055118	EFO_0006344	—	—	—	—	—	1	1
Metabolic bone diseases	D001851	—	—	—	—	—	—	1	1
Driving under the influence	D000066448	—	—	—	—	—	—	1	1

Show 4 more

Epidemiology

Epidemiological information for investigational and approved indications

View more details

Drug

General

Drug common name	Interferon beta-1a
INN	—
Description	Interferon beta precursor (IFN-beta) (Fibroblast interferon)
Classification	Protein
Drug class	—
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)	—